Webinar on Demand: Why the Battle for Future Market Share is Increasingly Won Before Phase 3
- Erin Rooney
- 2 days ago
- 1 min read
Most products that stumble post-approval don’t fail on efficacy; they fail because they weren’t built with the market in mind. Our recent webinar, Why the Battle for Future Market Share is Increasingly Won Before Phase 3, brought together experts from across biotech, investment, clinical, and commercial to discuss how to design for adoption, not just approval.
During the discussion, our expert panel shared fresh perspectives on:
Why pivotal trial design choices shape future commercial outcomes
How investors and executives evaluate adoption risk before Phase 3
Practical steps for building differentiation that resonates with payers, physicians, and patients
Webinar On Demand Featured Panelists
Managing Partner, Litmys, LLC
Chairman & CEO, Xontogeny;
Portfolio Manager, Perceptive Advisors
CEO, ONL Therapeutics
Chief Medical & Scientific Officer, Worldwide Clinical Trials
Continue the Conversation
If you’d like to talk through how these ideas could apply to your own pipeline, reach out anytime at harris.kaplan@litmys.com — we’d love to connect.